Last year, Yeda Research and Development, the tech transfer office of the Weizmann Institute, sued ImClone and Sanofi-Aventis over the Erbitux patent. (The patent was owned by the latter and licensed ...

This market is estimated to be worth $61.5 billion by 2032, and Sanofi (NASDAQ:SNY)'s early mover advantage should provide it with key patents that it can milk for most of the market's early ...

Glaxo’s patent for Zantac’s active ingredient ... with the exception of Delaware where the majority of the cases are pending.